ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A

Investigator: Diane Havlir, MD
Sponsor: Adamas Pharmaceuticals, Inc

Location(s): United States


This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.